We demonstrate that psoriasis coexists with a state of vascular inflammation that is compatible with an increased risk of cardiovascular events. Treatment with anti-TNFα and anti-IL-17 drugs prevents leukocyte recruitment by the endothelium and protects against the onset of thrombosis, effects that are not attributable to anti-IL-12/23. These results endorse the appropriateness of earlier initiation of treatment of psoriatic patients at a high risk of developing CV with selected biologics.
